(NASDAQ: PTCT) Ptc Therapeutics's forecast annual revenue growth rate of -19.94% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.25%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.49%.
Ptc Therapeutics's revenue in 2025 is $1,772,758,000.On average, 6 Wall Street analysts forecast PTCT's revenue for 2025 to be $137,475,975,620, with the lowest PTCT revenue forecast at $130,884,248,606, and the highest PTCT revenue forecast at $142,868,702,449. On average, 6 Wall Street analysts forecast PTCT's revenue for 2026 to be $73,914,065,578, with the lowest PTCT revenue forecast at $60,171,928,825, and the highest PTCT revenue forecast at $83,925,257,419.
In 2027, PTCT is forecast to generate $90,606,782,635 in revenue, with the lowest revenue forecast at $69,658,993,999 and the highest revenue forecast at $110,959,826,600.